.jpg "Savara Inc (NASDAQ: SVRA)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara Inc (NASDAQ: SVRA), Portola Pharma (NASDAQ: PTLA) and Ultragenyx (NASDAQ: RARE) with bullish sentiments.
Savara Inc (NASDAQ: SVRA)
Canaccord Genuity analyst Dewey Steadman reiterated a Buy rating on Savara Inc (NASDAQ: SVRA) yesterday and set a price target of $25. The company’s shares opened today at $9.35.
Steadman commented:
“We see Savara setting up for several important data catalysts that could start flowing through by the end of 2018 and throughout 2019. Savara’s three core programs – Molgradex PAP, Molgradex NTM and AeroVanc – give it several shots on goal for rare pulmonary diseases and make for an increasingly interesting biotech story that’s starting to gain notice in the investment community. We reiterate our BUY rating and $25 DCF- driven PT on SVRA shares.”
According to TipRanks.com, Steadman ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.4% and a 37.1% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Cardiome Pharma Corp.
Savara Inc has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.
See today’s analyst top recommended stocks >>
Portola Pharma (NASDAQ: PTLA)
In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Portola Pharma (NASDAQ: PTLA), with a price target of $65. The company’s shares opened today at $41.18.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.4% and a 51.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.
Currently, the analyst consensus on Portola Pharma is Strong Buy and the average price target is $60.80, representing a 47.6% upside.
In a report issued on April 30, Oppenheimer also reiterated a Buy rating on the stock with a $67 price target.
Ultragenyx (NASDAQ: RARE)
Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Ultragenyx (NASDAQ: RARE) yesterday and set a price target of $80. The company’s shares opened today at $59.76.
According to TipRanks.com, Lee is a 4-star analyst with an average return of 4.4% and a 47.1% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Ultragenyx is Strong Buy and the average price target is $71.40, representing a 19.5% upside.
In a report issued on May 7, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
